Fresenius Medcare: Q3 beats consensus
(CercleFinance.com) - Fresenius Medical Care, the subsidiary of Fresenius that is specialised in dialysis, has announced Q3 adjusted EPS that is up 8% at 1.
21 euro, fifteen cents above consensus.
Again in adjusted terms, operating profit inched up 1% to 599 million euros, for revenues that are up 8% at nearly 4.4 billion euros (+5% at constant exchange rates), with record growth in home dialysis in North America.
For 2019, Fresenius MedCare confirms its growth target range of between -2 and +2% for adjusted net income, and between
+3% and +7% for adjusted sales. For 2020, it anticipates mid-to-high single-digit growth.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
21 euro, fifteen cents above consensus.
Again in adjusted terms, operating profit inched up 1% to 599 million euros, for revenues that are up 8% at nearly 4.4 billion euros (+5% at constant exchange rates), with record growth in home dialysis in North America.
For 2019, Fresenius MedCare confirms its growth target range of between -2 and +2% for adjusted net income, and between
+3% and +7% for adjusted sales. For 2020, it anticipates mid-to-high single-digit growth.
Copyright (c) 2019 CercleFinance.com. All rights reserved.